Latest News for Evonik Indus Stock (OTC:EVKIF)

Evonik Industries is a German chemical company offering a mix of speciality and commodity chemical products. It has a number-one to -three market position in 80% of its businesses. Around 45% of sales are generated in Europe, while the key markets of North America and Asia account for 25% and 20% of sales, respectively. The company is organized into four major segments: specialty additives, smart materials, nutrition and care, and performance materials.

News

Movers & Shakers

Intraday Update

Markets

Movers

Trading Ideas

General

AAWW

ABMD

ACAN

ACRGF

ADAP

ADPT

ADRO

AIHS

AKCA

ALBO

ALKS

ALNA

AMTD

ANDE

ANGI

ANGO

AOBC

ARHVF

ASMB

ASRT

ASTC

Adtalem Global Education Inc. Common Stock

ATGE

AUPH

AUSAF

AVGR

AWLCF

AWSM

AXGN

BABYF

BCOR

BEAT

BERY

BGFT

BICX

BKCC

BLUE

BMRN

BNFT

BOCH

BOMN

BORR

BOSSY

BREW

BTHCF

BTKRF

BYZN

CADMF

CBDS

CBIIF

CCHWF

CDBMF

CDTI

CEIX

CHNC

CHOOF

CHRA

CHWY

CLVS

CLXT

CNNXF

CNONF

CRBP

CRVS

CSLT

CSTL

CTMX

CTRA

CTST

CVVUF

CWBR

CXXIF

CYTR

DFFN

DIIBF

DLPH

DNOW

DRIO

DTIL

DXBRF

EEVVF

EGRNF

ELGX

ELOX

EMERALD HEALTH THERAPUTCS by Emerald Health Therapeutics Inc.

EMHTF

ENBL

Stocks That Hit 52-Week Lows On Wednesday

EVONIK INDUSTRIES AG by Evonik Industries AG

Evonik Industries AG

A recent&nbsp;academic case study, published on April 22, examined&nbsp;using&nbsp;Amgen Inc&#8217;s&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) Blincyto, a bispecific CD3xCD19 T-cell engager, to treat a patient with severe systemic sclerosis.&nbsp;
The findings have implications for&nbsp;Cullinan Therapeutics Inc&#8217;s&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGEM#NASDAQ">CGEM</a>) CLN-978, a similar CD19xCD3 bispecific T-cell engager.
Most recently, Cullinan Therapeutics, formerly&nbsp;Cullinan Oncology, announced its plans to expand into autoimmune diseases and intends to pursue the development of CLN-978 in autoimmune diseases, with systemic lupus erythematosus&nbsp;<a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38277370/cullinan-shifts-focus-from-oncology-to-autoimmune-disorders-raises-280m-via-equity" rel="noreferrer noopener">(SLE) as a first indication</a>.&nbsp;
William Blair&nbsp;notes that the case report demonstrates that Blincyto effectively treated a patient with severe systemic sclerosis, leading to rapid B-cell depletion and symptom improvement without increasing infection risk or affecting antibody levels.
This&nbsp;suggests the potential for using B-cell-depleting therapy in autoimmune diseases like systemic lupus erythematosus (SLE),&nbsp;offering easier administration&nbsp;than CAR-T therapy.&nbsp;
CLN-978&#8217;s development will initially target SLE, with Phase 1 submission planned for the third quarter.
William Blair rates&nbsp;<a target="_blank" href="https://www.benzinga.com/quote/CGEM/analyst-ratings" rel="noreferrer noopener">Cullinan shares Outperform</a>&nbsp;based on the significant potential of CLN-619 for endometrial and cervical cancer,&nbsp;zipalertinib&nbsp;for exon 20 mutant lung cancer, CLN-049 for leukemia, and CLN-978 for autoimmune diseases.&nbsp;
They believe the fair value of each share is $33.
Updated data for CLN-619, expected in the second quarter of 2024, will be a&nbsp;key&nbsp;catalyst for the company, along with updates for CLN-978 in lupus and other autoimmune indications.&nbsp;
The development of Cullinan&#8217;s other early-stage oncology assets would provide additional upside.
Earlier Wednesday, Cullinan Therapeutics announced that clinical data from its Phase 1 trial of CLN-619 in patients with advanced solid tumors will&nbsp;be presented&nbsp;at the 2024 American&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/04/g38405740/cullinan-therapeutics-to-present-clinical-data-from-phase-1-study-evaluating-novel-anti-micab-anti" rel="noreferrer noopener">Society of Clinical Oncology</a>.
The data will include the first results from the dose escalation cohort of CLN-619 in combination with checkpoint inhibitor pembrolizumab and updated results from the monotherapy dose-escalation cohort in patients with advanced solid tumors.
Price Action: CGEM shares are up 15.10% at $19.18 at the last check Wednesday.
Photo via PublicDomainPictures from Pixabay

Analyst Color

Biotech

Health Care

Analyst Ratings

AMGN

CGEM

Why Is Cullinan Therapeutics Stock Trading Higher On Wednesday?

HSBC analyst Michael Tyndall maintains Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) with a Reduce and lowers the price target from $138 to $120.

Price Target

TSLA

HSBC Maintains Reduce on Tesla, Lowers Price Target to $120

Streaming giant Netflix Inc (NASDQ: NFLX) is upping its sports game in 2024 with several news items and the premiere of a comedy roast of Tom Brady, one of the greatest<a href="https://www.benzinga.com/news/23/02/30666186/quarterback-tom-brady-the-goat-announces-nfl-retirement-at-age-44"> NFL players of all time.</a>
What Happened: For years, Netflix had a strategy of <a href="https://www.benzinga.com/general/entertainment/23/12/36222143/netflix-lands-more-live-sports-how-success-of-docuseries-helped-pave-the-way">launching sports-adjacent content,</a> which includes docuseries on sports like Formula 1, tennis, golf and the Tour de France.
With a push into football content, which included the 2023 series "Quarterback," Netflix is now ready to add another direction for sports content.
The streaming company will air a live comedy roast of Tom Brady, titled "The Greatest Roast of All Time: Tom Brady."
An acronym of GROAT for the roast is a play on GOAT, an acronym which means "Greatest of All Time," and is often used to describe legends like Brady.
This marks the first live roast for Netflix and comes as the company has expanded its live content with several live sports specials and a live comedy special featuring Chris Rock.
The roast will be part of the "Netflix Is a Joke Fest" and air on May 5 at 8 p.m. ET, exclusively on Netflix.
Comedian Kevin Hart serves as the host of the roast, with comedian and well-known roaster Jeff Ross also serving as a roaster of Brady. No other guests have been confirmed for the event, with a trailer saying there will be a lineup of surprise guests. Roasters could include athletes, comedians and celebrities.
"No Helmets. No Mercy. No Brady Rule," the trailer reads.
Brady says "I'm unroastable" in the trailer.
Related Link: <a href="https://www.benzinga.com/news/earnings/24/04/38324337/netflix-q1-earnings-highlights-revenue-beat-eps-beat-9-33-million-paid-subs-added-ad-tier-plan-upda">Netflix Q1 Earnings Highlights: Revenue Beat, EPS Beat, 9.33 Million Paid Subs Added, Ad-Tier Plan Update And More</a>
Why It's Important: Brady retired after the 2023 season, which came after returning to the league from a previous retirement decision.
The NFL quarterback retired as the record holder in passing yards, passing touchdowns, NFL Playoff passing yards, NFL Playoff touchdowns and many other records. The winningest NFL quarterback won seven Super Bowls in 10 Super Bowl appearances and won a record five Super Bowl MVP awards.
The roast of Brady marks another move into sports and live content by Netflix, which comes after "The Netflix Slam" aired in March 2024 featuring tennis stars Rafael Nadal and Carlos Alcaraz.
Netflix has also aired a live golf special with golfers and race car drivers.
The company launches perhaps its biggest sporting event ever with a <a href="https://www.benzinga.com/general/entertainment/24/03/37540711/jake-paul-vs-mike-tyson-coming-to-netflix-biggest-fight-in-history">live boxing special </a>featuring Mike Tyson and Jake Paul on July 20.
Netflix also recently <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38146011/wwe-could-be-a-netflix-game-changer-capitalizing-on-opportunities-to-maximize-fan-g">signed a deal</a> with World Wrestling Entertainment, which is a unit of TKO Group Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TKO#NYSE">TKO</a>), that will boost its sports content library.
"Receiver," which is a spinoff of "Quarterback" will air on Netflix in summer 2024 and feature NFL players Davante Adams (Las Vegas Raiders), Justin Jefferson (Minnesota Vikings), George Kittle (San Francisco 49ers), Deebo Samuel (San Francisco 49ers) and Amon-Ra St. Brown (Detroit Lions).
Netflix has aired several sports documentaries. It also bid on the media rights to several sports leagues, but has been less aggressive in bidding on sports rights in recent months, saying it wanted to focus on sports-adjacent programming such as docuseries and potentially one-off live events.
&#8220;We aren&#8217;t anti-sports, we&#8217;re pro-profit,&#8221; Netflix co-CEO Ted Sarandos said in January 2023 <a href="https://www.benzinga.com/general/entertainment/23/07/33308114/netflix-doesnt-want-to-live-sports-and-chill-were-happy-with-sports-adjacent-programming-ce">when asked about sports rights.</a>
While the company hasn't won any rights for live matches of the four major North American sports leagues, Netflix continues to push deeper into the world of sports content.
 NFLX Price Action: Netflix shares are down 3.63% to $556.55 on Wednesday versus a 52-week trading range of $315.62 to $639.
Read Next: <a href="https://www.benzinga.com/news/23/08/33552415/from-football-to-futbol-tom-brady-buys-stake-in-this-team-joining-list-of-celebrities-athletes-with">From Football To Futbol: Tom Brady Buys Stake In This Team, Joining List Of Celebrities, Athletes With Pro Sports Ownership</a>
Photos: Brady, Shutterstock; Netflix, Unsplash

Entertainment

Sports

NFLX

Tom Brady To Be Roasted In Live Netflix Special: NFL GOAT Becomes GROAT In Streaming Giant's Continuing Bet On Sports Content

Self-storage center real estate investment trusts (REITs) are companies that specialize in owning and operating income-generating storage facilities, commonly known as self-storage centers. Self-store center REITs invest in properties where individuals and businesses can rent space to store their belongings, such as furniture, household items, business inventory, and vehicles of all types.
Investors in self-storage center REITs benefit from the income generated through leasing storage units to tenants. The demand for self-storage has been driven by various factors, including residential moves, downsizing, and businesses seeking additional space.
If you're interested in investing in a self-storage REIT, here are two you could buy today.
<h2 class="wp-block-heading">Don't Miss:</h2>
<ul>
<li>Investing in real estate just got a whole lot simpler. This <a href="https://www.benzinga.com/go/bezos-landlord">Jeff Bezos-backed startup will allow you to become a landlord</a> in just 10 minutes, and you only need $100.</li>
<li>Want To Grow Your Wealth Passively? Unlock Real Wealth with <a href="https://www.benzinga.com/money/cityfunds-yield">Cityfunds&#8217; Exclusive 8% Yield Fund</a>.</li>
</ul>
<h2 class="wp-block-heading">CubeSmart</h2>
CubeSmart (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CUBE#NYSE">CUBE</a>) is the third largest owner and operator of self-storage facilities in the United States with a portfolio of <a href="https://s201.q4cdn.com/604002580/files/doc_presentations/2024/Mar/04/cube-ir-presentation-march-2024-final.pdf">1,406 properties</a> across 178 markets in 41 states and the District of Columbia.
CubeSmart currently pays a quarterly dividend of $0.51 per share, equating to an annualized dividend of $2.04 per share, which gives its stock a yield of about 4.9% at the time of this writing.
In addition to sporting a high yield, CubeSmart is a dividend-growth superstar. Its <a href="https://investors.cubesmart.com/news--events/news-details/2023/CubeSmart-Announces-4.1-Increase-in-Quarterly-Common-Dividend/default.aspx">4.1% hike in December</a> marked the 14th consecutive year in which it has raised its annual dividend payment.
<h2 class="wp-block-heading">Trending:</h2>
<ul>
<li>Want to Create a Passive Income Stream? <a href="https://www.benzinga.com/go/grow-wealth-passively">These High-Yield Real Estate Notes Might Be Your Holy Grail</a></li>
</ul>
<h2 class="wp-block-heading">National Storage Affiliates Trust</h2>
National Storage Affiliates Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NSA#NYSE">NSA</a>) is a leading owner and operator of self-storage facilities in the U.S. with ownership interests in <a href="https://d1io3yog0oux5.cloudfront.net/_7cb5f849447bdcf18d510090a08d741e/nationalstorageaffiliates/db/226/5086/pdf/NSA+Presentation_March+Update+2024_FINAL.pdf">1,050 properties</a> containing approximately 68.6 million rentable square feet across 42 states and Puerto Rico.
National Storage currently pays a quarterly dividend of $0.56 per share, equating to an annualized dividend of $2.24 per share, which gives its stock a yield of about 6.3% at the time of this writing.&nbsp;
Like CubeSmart, National Storage is a dividend-growth superstar. It has raised its annual dividend payment every year since its initial public offering in 2015, putting it on track for 2024 to mark the ninth consecutive year with an increase.
<h2 class="wp-block-heading">Read Next:</h2>
<ul>
<li>Elon Musk Is Bullish On Austin. Here&#8217;s <a href="https://www.benzinga.com/go/musk-austin">How To Invest In The City&#8217;s Growth Before He Floods It With New Tech Workers</a>.</li>
<li>Whole Foods&#8217; Landlord Has Achieved A 15% Net IRR For Accredited Investors Since 2015 — <a href="https://www.benzinga.com/go/whole-foods-landlord">Discover The Latest Investment Opportunities On Its Platform</a>.</li>
</ul>
Image Credit: Shutterstock

REIT

Real Estate

CUBE

These Self-Storage REITs Yield Up to 6.3% and Have Track Records of Dividend Growth

Nine months after the U.S. launch of&nbsp;Eisai Limited&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/ESALY#OTC">ESALY</a>) and&nbsp;Biogen Inc&#8217;s&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) Leqembi, the first drug shown to slow Alzheimer&#8217;s progression, adoption faces hurdles due to skepticism among some doctors.&nbsp;
Initially hopeful, Alzheimer&#8217;s experts anticipated challenges with Leqembi&#8217;s requirements, including frequent infusions and diagnostic tests, leading to slow adoption&nbsp;<a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/23/07/33148410/expanded-medicare-coverage-for-biogen-eisais-leqembi-signals-a-turning-point-in-alz" rel="noreferrer noopener">after FDA approval</a>.&nbsp;
Interviews with 20 neurologists and geriatricians revealed concerns about efficacy, costs, and risks, hampering widespread prescription.
Read Next:&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/03/37897025/european-medicines-agency-delays-approval-decision-for-biogen-eisai-partnered-alzheimers-drug-lec" rel="noreferrer noopener">European Medicines Agency Delays Approval Decision For Biogen-Eisai Partnered Alzheimer&#8217;s Drug Lecanemab</a>.
Reuters highlighted that seven interviewed doctors cited skepticism, while six highlighted &#8220;therapeutic nihilism&#8221; as a significant barrier to Leqembi adoption.&nbsp;
Dr. Reisa Sperling likened skepticism to past fatalistic attitudes toward cancer treatment. Eisai&#8217;s chief administrative officer,&nbsp;Alex Scott, acknowledged skepticism&#8217;s impact, citing historical skepticism toward Alzheimer&#8217;s research.
In trials, Leqembi,&nbsp;targeting&nbsp;amyloid, showed a 27%&nbsp;cognition decline slowdown.&nbsp;However, adoption has been sluggish, with only a fraction of intended patients receiving treatment.&nbsp;
Factors include long adoption cycles for new drugs and concerns about Leqembi&#8217;s efficacy and costs.
Despite FDA approval, less than half of U.S. neurologists recommend Leqembi, citing limited patient benefit and significant risks.&nbsp;
Dr. Michael Greicius doubts Leqembi&#8217;s meaningful patient benefits, given slim trial differences, Reuter writes.&nbsp;Dr. Eric Widera and Donna Fick caution about the drug&#8217;s risks and unclear benefits.
Some physicians have expressed worries regarding the potential for brain swelling and bleeding linked to Leqembi.&nbsp;
They&#8217;ve also highlighted concerns about the financial burden imposed by the drug&#8217;s&nbsp;$26,500&nbsp;yearly cost, along with the expenses related to regular MRIs and bi-monthly infusions.
Reuters notes that of the 10,000 Americans the companies hoped to treat by the end of March, Eisai announced that only a couple thousand had begun treatment as of January.&nbsp;
Biogen and Eisai intend to increase their sales force by 30%, aiming for 100,000 patients by 2026.
In its first-quarter earnings release, Biogen said Leqembi launch uptake accelerated with first-quarter global in-market sales of approximately&nbsp;$19 million, nearly triple the fourth quarter of 2023, and patients on therapy increasing&nbsp;nearly&nbsp;2.5 times&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/04/38410191/biogens-leqembi-commercial-ramp-up-modest-but-up-ticking-reports-mixed-bag-q1-earnings" rel="noreferrer noopener">since the end of 2023</a>.&nbsp;
Read Next:&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/01/36871446/biogen-gives-up-on-aduhelm-efforts-after-two-years-of-controversial-fda-accelerated-approval-for-" rel="noreferrer noopener">Biogen Gives Up On Aduhelm Efforts After Two Years Of Controversial FDA Accelerated Approval For Alzheimer&#8217;s, Shifts Focus On Newer Medicines</a>.
Price Action:&nbsp;BIIB shares are up 3.36% at $199.68&nbsp;at the last check Wednesday.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo by Gerd Altmann via Pixabay

Large Cap

BIIB

ESALY

Biogen/Eisai's Popular Alzheimer's Drug Leqembi Is Seeing Slow Adoption - Here's Why

Shares of Visa Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>) were climbing in early trading on Wednesday, after <a href="https://www.benzinga.com/markets/equities/24/04/38400226/whats-going-on-with-visa-shares-wednesday">the company reported an earnings beat for its fiscal second quarter</a>.
Here are some key analyst takeaways from the release.
<ul>
<li>Goldman Sachs analyst Will Nance reiterated a Buy rating, while raising the price target from $328 to $335.</li>
<li>Oppenheimer analyst Jake Kooyman maintained an Outperform rating, while lifting the price target from $297 to $299.</li>
<li>Wedbush analyst Moshe Katri reaffirmed an Outperform rating, while raising the price target from $280 to $300.</li>
<li>BMO Capital Markets analyst Rufus Hone reiterated an Outperform rating and price target of $300.</li>
<li>Keefe Bruyette &amp; Woods analyst Sanjay Sakhrani maintained an Outperform rating and price target of $325.</li>
<li>Mizuho Securities analyst Dan Dolev reaffirmed a Neutral rating and price target of $265.</li>
</ul>
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
Goldman Sachs: Visa reported "solid" quarterly results. Earnings of $2.51 per share beat the consensus of $2.44 per share. The results were driven by "broadly inline trends in revenues aided by a large beat on incentives," Nance said. 
Softer trends in April were seen by the company as "largely a function of Easter timing."
Although management lowered the volume guidance to reflect softer results in the Asia Pacific (APAC) region, they broadly reiterated expectations for improving ticket sizes in both the US and the rest of the world excluding APAC for the rest of the year, "which had been an area of skepticism among investors," the analyst further stated.
Oppenheimer: Visa&#8217;s non-GAAP earnings grew by 20% to $2.51 per share, while net revenue on a constant currency basis rose 10% year-over-year to $8.6 billion, with both figures beating expectations, Kooyman said. 
"Other revenue largely drove the delta versus the Street, which increased 37% year over year driven by strong consulting and marketing services revenue growth," he added.
"Moreover, overall spending trends remained solid, evidenced by an 8% year-over-year increase in payments volume, 11% rise in processed transactions and a 16% gain in constant currency cross-border volume," the analyst wrote. Visa remains on track to generate low double-digit top-line growth and earnings growth in the low teens, he further stated.
Wedbush: Visa reported stronger-than-expected quarterly results and reiterated its full-year guidance, Katri said. Payment volume growth accelerated sequentially by 100 basis points (bps) in the US, but slowed internationally by 100 bps, keeping the aggregate consistent, he added.
"While FY24 guidance was reiterated, management reset expectations for Total volume growth to high single digits from low double digits due to APAC travel slowing recovery," the analyst wrote. "This is being offset by stronger than expected performance in high-yield eCommerce," he further stated.
BMO Capital Markets: Given Visa's "solid" quarterly results, the reiterated revenue guidance for the full year appears "de-risked, supported by accelerating VAS/ New Flows growth, resilient cross-border trends and slower 2H growth in incentive payments," Hone wrote in a note.
"While US payment volume in the first 3 weeks of April are tracking +5% YoY (down slightly from ~6% YoY in March/FY2Q24), Visa noted that the earlier Easter timing this year accounted for the slight sequential deceleration," he added.
Keefe, Bruyette &amp; Woods: Visa reported an earnings beat "driven primarily by client incentives (+$0.10/share), with some added benefit from higher other income (+$0.02/share) and a lower tax rate (+$0.01/share)," Sakhrani said. 
He added, however, that the beat was partially offset by a decline in gross revenues, higher opex, and an increase in share count.
"Visa's results are tracking in-line with expectations, which is a positive relative to intra-quarter concerns that full year targets may prove to be too high," the analyst further stated.
Mizuho Securities: Visa's strong quarterly results "marked by accelerating US volumes (+6% vs. +5%) and unchanged guide should drive a sigh of relief rally in the stock," Dolev said.
Although the company maintaining its full-year revenue guidance is "a key positive," the slower trends in April "can be a potential hurdle" to achieving the same pace of revenue growth in the second half of the year, he added.
V Price Action: Shares of Visa had risen by 0.86% to $276.47 at the time of publication on Wednesday.
Now Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38412499/treasury-yields-rise-tesla-jumps-on-cheaper-model-pledge-yen-plummets-to-34-year-lows-what">Treasury Yields Rise, Tesla Jumps On Cheaper Model Pledge, Yen Plummets To 34-Year Lows: What&#8217;s Driving Markets Wednesday?</a>

Earnings Misses

Reiteration

Visa Delivers 'Solid' Earnings Beat, 6 Analysts Provide Key Takeaways: 'Blame Easter For Softer Trends'

Citigroup analyst Jason Gursky maintains RTX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RTX#NYSE">RTX</a>) with a Neutral and raises the price target from $95 to $110.

Citigroup Maintains Neutral on RTX, Raises Price Target to $110

Citigroup analyst Jon Tower maintains Texas Roadhouse (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXRH#NASDAQ">TXRH</a>) with a Buy and raises the price target from $162 to $178.

TXRH

Citigroup Maintains Buy on Texas Roadhouse, Raises Price Target to $178

Argus Research analyst Stephen Biggar maintains Blackstone (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BX#NYSE">BX</a>) with a Buy and raises the price target from $133 to $135.

Argus Research Maintains Buy on Blackstone, Raises Price Target to $135

Citigroup analyst Ben Gerlinger maintains Webster Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WBS#NYSE">WBS</a>) with a Buy and lowers the price target from $60 to $55.

Citigroup Maintains Buy on Webster Finl, Lowers Price Target to $55

RBC Capital analyst Tom Narayan maintains General Motors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) with a Outperform and raises the price target from $56 to $58.

RBC Capital Maintains Outperform on General Motors, Raises Price Target to $58

On Wednesday,&nbsp;Humana&nbsp;Inc&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>), in its first quarter earnings remarks, said the company&nbsp;<a target="_blank" href="https://humana.gcs-web.com/static-files/4a3a2261-3d15-4997-8abc-cec1ed05876d" rel="noreferrer noopener">withdrew</a>&nbsp;its already lowered 2025 profit forecast, citing disappointing government Medicare Advantage (MA)&nbsp;<a target="_blank" href="https://www.benzinga.com/government/24/04/38034935/unitedhealth-humana-cvs-shares-are-sliding-monday-whats-going-on" rel="noreferrer noopener">reimbursement rates</a>.
The insurance firm said the final MA rate notice is&nbsp;not sufficient&nbsp;to address the current medical&nbsp;<a target="_blank" href="https://www.benzinga.com/news/earnings/24/01/36778837/humana-blames-medicare-advantage-as-stock-falls-after-larger-than-expected-quarterly-loss-grim-outl" rel="noreferrer noopener">cost trend environment</a>.
Humana&#8217;s medical benefit ratio &#8211; the&nbsp;percentage of premiums spent on medical care &#8211; rose to&nbsp;<a target="_blank" href="https://www.benzinga.com/news/earnings/24/04/38405775/humana-boosts-medicare-advantage-membership-2024-forecast-as-q1-earnings-performance-exceeds-expect" rel="noreferrer noopener">88.9% in the first quarter</a>.
In its fourth quarter 2023 earnings release, Humana&nbsp;<a target="_blank" href="https://humana.gcs-web.com/static-files/f601f75a-3e88-4287-a27f-e875be221ad1" rel="noreferrer noopener">said</a>, &#8220;Although we intend to prioritize margin recovery over membership growth in the near term, we no longer believe the previously communicated $37 Adjusted EPS target for 2025 is achievable.&#8221;
&#8220;It is our intent&nbsp;to deliver $6 to $10 of Adjusted EPS growth in 2025 through MA pricing actions, earnings growth in other lines of business, as well as our ongoing productivity and trend mitigation initiatives,&#8221; the company added.
In its first quarter 2024 earnings, the company said: &#8220;Considering the significant difference between the final rate notice and our previous funding assumption, combined with the inherent pricing limitations imposed by the Total Beneficiary Cost (TBC) change thresholds, we no longer believe $6 to $10 of Adjusted EPS growth is the appropriate target range for 2025.&#8221;
Humana said, &#8220;Our 2025 Adjusted EPS growth outlook will&nbsp;be impacted&nbsp;by several variables into which we will not have clear visibility until later this year.&nbsp;As a result, we believe&nbsp;it is prudent to provide&nbsp;more specific guidance for 2025 once we have greater clarity.&#8221;
Humana noted that pricing decisions for the 2025 MA bids are&nbsp;being&nbsp;finalized and will be submitted by the first Monday in June.
The company will provide an update on&nbsp;bid strategy&nbsp;post finalization, with a further update in the Fall once we have visibility into competitor plans and expected membership implications.
Price Action:&nbsp;HUM shares are down 3.75% at $315.68&nbsp;at&nbsp;the last check Wednesday.

Guidance

Tech

Humana Withdraws Its Already Lowered 2025 Profit Guidance

Citigroup analyst Filippo Falorni maintains Kimberly-Clark (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMB#NYSE">KMB</a>) with a Sell and raises the price target from $111 to $125.

Citigroup Maintains Sell on Kimberly-Clark, Raises Price Target to $125

Citigroup analyst George Kurosawa maintains Manhattan Associates (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MANH#NASDAQ">MANH</a>) with a Neutral and lowers the price target from $260 to $220.

MANH

Citigroup Maintains Neutral on Manhattan Associates, Lowers Price Target to $220

Whales with a lot of money to spend have taken a noticeably bearish stance on Salesforce.
Looking at options history for Salesforce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>) we detected 17 trades.
If we consider the specifics of each trade, it is accurate to state that 41% of the investors opened trades with bullish expectations and 47% with bearish.
From the overall spotted trades, 4 are puts, for a total amount of $295,628 and 13, calls, for a total amount of $888,921.
<h3>What's The Price Target?</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $200.0 and $410.0 for Salesforce, spanning the last three months.
<h3>Analyzing Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Salesforce's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Salesforce's substantial trades, within a strike price spectrum from $200.0 to $410.0 over the preceding 30 days.
<h3>Salesforce Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1713982580_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CRM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$18.15</td>
<td>$18.05</td>
<td>$18.15</td>
<td>$330.00</td>
<td>$168.7K</td>
<td style="text-align: right;">145</td>
<td style="text-align: right;">8</td>
</tr>
<tr>
<td>CRM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$45.15</td>
<td>$44.0</td>
<td>$44.0</td>
<td>$300.00</td>
<td>$158.4K</td>
<td style="text-align: right;">397</td>
<td style="text-align: right;">40</td>
</tr>
<tr>
<td>CRM</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>03/21/25</td>
<td>$67.35</td>
<td>$65.8</td>
<td>$66.5</td>
<td>$230.00</td>
<td>$133.0K</td>
<td style="text-align: right;">16</td>
<td style="text-align: right;">10</td>
</tr>
<tr>
<td>CRM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$21.85</td>
<td>$21.65</td>
<td>$21.65</td>
<td>$300.00</td>
<td>$99.5K</td>
<td style="text-align: right;">146</td>
<td style="text-align: right;">64</td>
</tr>
<tr>
<td>CRM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$70.95</td>
<td>$68.5</td>
<td>$69.0</td>
<td>$230.00</td>
<td>$69.0K</td>
<td style="text-align: right;">16</td>
<td style="text-align: right;">10</td>
</tr>
</tbody>
</table>

<h3>About Salesforce</h3>
Salesforce Inc provides enterprise cloud computing solutions. The company offers customer relationship management technology that brings companies and customers together. Its Customer 360 platform helps the group to deliver a single source of truth, connecting customer data across systems, apps, and devices to help companies sell, service, market, and conduct commerce. It also offers Service Cloud for customer support, Marketing Cloud for digital marketing campaigns, Commerce Cloud as an e-commerce engine, the Salesforce Platform, which allows enterprises to build applications, and other solutions, such as MuleSoft for data integration.
Following our analysis of the options activities associated with Salesforce, we pivot to a closer look at the company's own performance.
<h3>Where Is Salesforce Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 1,846,367, with CRM's price up by 0.26%, positioned at $277.41.</li>
<li>RSI indicators show the stock to be may be approaching oversold.</li>
<li>Earnings announcement expected in 35 days.</li>
</ul>
<h3>Professional Analyst Ratings for Salesforce</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $351.0.
<ul>
<li>An analyst from Stifel persists with their Buy rating on Salesforce, maintaining a target price of $350. </li>
<li>Reflecting concerns, an analyst from RBC Capital lowers its rating to Outperform with a new price target of $350.</li>
<li>An analyst from Needham downgraded its action to Buy with a price target of $345. </li>
<li>Maintaining their stance, an analyst from Jefferies continues to hold a Buy rating for Salesforce, targeting a price of $360. </li>
<li>In a cautious move, an analyst from RBC Capital downgraded its rating to Outperform, setting a price target of $350. </li>
</ul>
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Salesforce options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

Looking At Salesforce's Recent Unusual Options Activity

Investors with a lot of money to spend have taken a bullish stance on Mobileye Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBLY#NASDAQ">MBLY</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with MBLY, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 9 uncommon options trades for Mobileye Global.
This isn't normal.
The overall sentiment of these big-money traders is split between 44% bullish and 44%, bearish.
Out of all of the special options we uncovered, 3 are puts, for a total amount of $161,832, and 6 are calls, for a total amount of $422,540.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $28.0 to $42.0 for Mobileye Global over the last 3 months. 
<h3>Volume &amp; Open Interest Trends</h3>
In terms of liquidity and interest, the mean open interest for Mobileye Global options trades today is 690.43 with a total volume of 1,266.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Mobileye Global's big money trades within a strike price range of $28.0 to $42.0 over the last 30 days.
<h3>Mobileye Global 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1713982574_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MBLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/17/24</td>
<td>$2.45</td>
<td>$2.4</td>
<td>$2.4</td>
<td>$31.00</td>
<td>$180.0K</td>
<td>2.2K</td>
<td style="text-align: right;">813</td>
</tr>
<tr>
<td>MBLY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$6.9</td>
<td>$6.6</td>
<td>$6.74</td>
<td>$30.00</td>
<td>$120.5K</td>
<td>1.2K</td>
<td style="text-align: right;">179</td>
</tr>
<tr>
<td>MBLY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/17/24</td>
<td>$7.1</td>
<td>$6.9</td>
<td>$7.0</td>
<td>$38.00</td>
<td>$66.5K</td>
<td>35</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>MBLY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/16/24</td>
<td>$11.2</td>
<td>$11.0</td>
<td>$11.0</td>
<td>$42.00</td>
<td>$61.6K</td>
<td>56</td>
<td style="text-align: right;">56</td>
</tr>
<tr>
<td>MBLY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$6.6</td>
<td>$6.4</td>
<td>$6.53</td>
<td>$29.00</td>
<td>$45.4K</td>
<td>210</td>
<td style="text-align: right;">66</td>
</tr>
</tbody>
</table>

<h3>About Mobileye Global</h3>
Mobileye Global Inc engages in the development and deployment of ADAS and autonomous driving technologies and solutions. It is building a portfolio of end-to-end ADAS and autonomous driving solutions to provide the capabilities needed for the future of autonomous driving, leveraging a comprehensive suite of purpose-built software and hardware technologies. Mobileye is the Company's only reportable operating segment. Its solutions comprise Driver Assist, Cloud-Enhanced Driver Assist, Mobileye SuperVision Lite, Mobileye SuperVision, Mobileye Chauffeur, Mobileye Drive, Self-Driving System &amp; Vehicles. It also provides data services to Expedite Maintenance Operations with AI-Powered Road Survey Technology.
Having examined the options trading patterns of Mobileye Global, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Where Is Mobileye Global Standing Right Now?</h3>
<ul>
<li>With a volume of 1,625,084, the price of MBLY is up 1.48% at $30.88. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 1 days.</li>
</ul>
<h3>Professional Analyst Ratings for Mobileye Global</h3>
In the last month, 2 experts released ratings on this stock with an average target price of $39.5.
<ul>
<li>Maintaining their stance, an analyst from JP Morgan continues to hold a Overweight rating for Mobileye Global, targeting a price of $38. </li>
<li>In a positive move, an analyst from Wolfe Research has upgraded their rating to Outperform and adjusted the price target to $41. </li>
</ul>
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Mobileye Global options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

MBLY

Spotlight on Mobileye Global: Analyzing the Surge in Options Activity

Financial giants have made a conspicuous bullish move on Lyft. Our analysis of options history for Lyft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYFT#NASDAQ">LYFT</a>) revealed 11 unusual trades.
Delving into the details, we found 63% of traders were bullish, while 36% showed bearish tendencies. Out of all the trades we spotted, 4 were puts, with a value of $164,232, and 7 were calls, valued at $1,166,313.
<h3>What's The Price Target?</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $14.0 and $27.0 for Lyft, spanning the last three months.
<h3>Volume &amp; Open Interest Trends</h3>
In today's trading context, the average open interest for options of Lyft stands at 2059.73, with a total volume reaching 1,463.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Lyft, situated within the strike price corridor from $14.0 to $27.0, throughout the last 30 days.
<h3>Lyft Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1713982569_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>LYFT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>07/19/24</td>
<td>$2.2</td>
<td>$2.17</td>
<td>$2.2</td>
<td>$17.00</td>
<td>$770.0K</td>
<td>1.6K</td>
<td style="text-align: right;">23</td>
</tr>
<tr>
<td>LYFT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/17/24</td>
<td>$2.76</td>
<td>$2.67</td>
<td>$2.67</td>
<td>$14.00</td>
<td>$114.0K</td>
<td>286</td>
<td style="text-align: right;">2</td>
</tr>
<tr>
<td>LYFT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/03/24</td>
<td>$0.56</td>
<td>$0.37</td>
<td>$0.37</td>
<td>$17.50</td>
<td>$108.6K</td>
<td>4.0K</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>LYFT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$12.05</td>
<td>$11.95</td>
<td>$12.0</td>
<td>$27.00</td>
<td>$73.2K</td>
<td>0</td>
<td style="text-align: right;">3</td>
</tr>
<tr>
<td>LYFT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/17/24</td>
<td>$1.31</td>
<td>$1.28</td>
<td>$1.3</td>
<td>$17.00</td>
<td>$65.0K</td>
<td>2.2K</td>
<td style="text-align: right;">546</td>
</tr>
</tbody>
</table>

<h3>About Lyft</h3>
Lyft is the second-largest ride-sharing service provider in the us and Canada, connecting riders and drivers over the Lyft app. Incorporated in 2013, Lyft offers a variety of rides via private vehicles, including traditional private rides, shared rides, and luxury ones. Besides ride-share, Lyft also has entered the bike- and scooter-share market to bring multimodal transportation options to users.
<h3>Present Market Standing of Lyft</h3>
<ul>
<li>With a volume of 12,069,459, the price of LYFT is down -2.48% at $16.5. </li>
<li>RSI indicators hint that the underlying stock may be approaching oversold.</li>
<li>Next earnings are expected to be released in 13 days.</li>
</ul>
<h3>What The Experts Say On Lyft</h3>
Over the past month, 2 industry analysts have shared their insights on this stock, proposing an average target price of $21.0.
<ul>
<li>An analyst from Wells Fargo has decided to maintain their Equal-Weight rating on Lyft, which currently sits at a price target of $18. </li>
<li>An analyst from Tigress Financial persists with their Buy rating on Lyft, maintaining a target price of $24. </li>
</ul>
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Lyft options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

LYFT

Lyft's Options: A Look at What the Big Money is Thinking

The Senate Committee on Health, Education, Labor, and Pensions is reportedly scrutinizing &nbsp;Novo Nordisk&nbsp;A/S&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) &#8216;s pricing strategies, particularly those of its diabetes and obesity&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/03/37989566/how-much-does-it-cost-to-make-novo-nordisks-ozempic-shockingly-low-against-1-000-price-tag-study-" rel="noreferrer noopener">medications, Ozempic and Wegovy</a>.
Senator Bernie Sanders emphasized the necessity of reducing prices to ensure accessibility for consumers and sustainability for governments.
Senator Sanders penned a letter to Novo Nordisk&#8217;s CEO, Lars Fruergaard Jorgensen, demanding internal communications regarding the pricing discrepancies between the U.S. and other countries.&nbsp;
The committee questioned why Wegovy, containing the same compound as Ozempic, bears a higher price tag, the New York Times&nbsp;<a target="_blank" href="https://www.nytimes.com/2024/04/24/well/live/ozempic-cost-senate.html?searchResultPosition=1" rel="noreferrer noopener">noted</a>. A response has been requested by May 8.
Senator Sanders also intended to investigate&nbsp;Eli Lilly And Co&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), the manufacturer of rival medications, Mounjaro and Zepbound, to address industry-wide pricing concerns.&nbsp;
With obesity affecting nearly 42% of American adults and over 11 percent with diabetes, ensuring affordability poses a significant challenge.
A recent study by the Kaiser Family Foundation (KFF) revealed that approximately 3.6 million overweight or obese patients with heart conditions covered under the U.S. Medicare program may become eligible for&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/03/37984877/insurance-coverage-for-weight-loss-drugs-elevance-cvs-health-become-first-to-extend-coverage-to-n" rel="noreferrer noopener">coverage of Wegovy</a>.&nbsp;
The study highlights that the expanded coverage would affect Medicare beneficiaries and other insurers&#8217; coverage for individuals with heart conditions.&nbsp;
Currently,&nbsp;Medicare prescription drug plans (Part D) administered by private insurers do not cover drugs approved solely for obesity.&nbsp;
However, new guidance suggests that drugs approved for secondary use Medicare covers could be eligible.
Citing the KFF study, Reuters highlights that the approval could open up Wegovy to over a quarter of the 13.7 million Medicare beneficiaries diagnosed with heart disease and obesity.&nbsp;
Among these eligible patients, approximately 1.9 million also have diabetes, making them already eligible for Medicare coverage of other drugs like Novo&#8217;s Ozempic.
Although some Part D plans have announced plans to cover Wegovy this year, broader coverage may be anticipated by 2025.&nbsp;
The extent of the drug&#8217;s coverage and its impact on Medicare spending will depend on various factors. These include the number of Part D plans adding coverage, potential restrictions on use such as prior authorization, and negotiated prices paid by plans.
Despite major insurance plans covering these medications to varying extents, rising costs have led to coverage restrictions and termination, exacerbating accessibility issues.&nbsp;
Medicaid and Medicare coverage disparities further compound the problem.
Price Action:&nbsp;NVO shares are down 1.91% at $126.18&nbsp;at the last check Wednesday.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photos courtesy: Shutterstock

Legal

What Are Pricing Strategies for Ozempic And Wegovy With Potential Medicare Coverage Expansion? Senate Committee Questions Novo Nordisk

Citigroup analyst Patrick Donnelly maintains Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) with a Buy and raises the price target from $280 to $290.

Citigroup Maintains Buy on Danaher, Raises Price Target to $290

Heineken NV&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/HEINY#OTC">HEINY</a>) clocked&nbsp;revenue&nbsp;<a target="_blank" href="https://www.heinekenholding.com/investors/media-releases/heineken-holding-nv-reports-2024-first-quarter-trading" rel="noreferrer noopener">growth&nbsp;</a>of 7.2% Y/Y in the first quarter of FY24 to 8.18 billion euros, driven by volume growth of 4.3% Y/Y and net revenue (beia) per hectolitre increase of&nbsp;4.9% Y/Y.
Beer volume increased 4.7% organically Y/Y on growth across all regions, a sequential improvement in the performance of the business, boosted by calendar and one-off effects.&nbsp;
Beer volume came ahead of the company-provided market expectations of 2.5%,&nbsp;reported&nbsp;WSJ.
In particular, the Americas and Europe regions benefitted from the earlier timing of Easter&nbsp;and&nbsp;the Africa &amp; Middle East.
Also, the&nbsp;Asia Pacific regions gained from a soft comparable base last year due to one-off effects in Vietnam and Nigeria.
Also Read:&nbsp;<a target="_blank" href="https://www.benzinga.com/markets/equities/23/08/34039199/cheers-to-no-cheers-heineken-closes-russian-operations-takes-300m-loss" rel="noreferrer noopener">Cheers To No Cheers: Heineken Closes Russian Operations, Takes €300M&nbsp;Loss</a>
Outlook: The company continues to expect FY24 operating&nbsp;profit (beia) to grow organically by a low- to high-single-digit and net profit (beia) organic growth to be lower than the operating profit (beia) organic growth.
Price Action: HEINY shares were trading higher by 1.39% at $49.71 at the last check Wednesday.
Photo: Engin Akyurt from Pixabay

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Latest News for Evonik Indus Stock (OTC:EVKIF)

Wednesday, October 02, 2019

Friday, November 16, 2018